Article Versions Notes

Gibson AJW, Dean ML, Litt I, Box A, Cheung WY, Navani V. Real-World Analysis of Post-Progression Treatment Patterns and Outcomes for EGFR Mutation-Positive Patients Treated with First-Line Osimertinib. Current Oncology. 2024; 31(5):2427-2440. https://doi.org/10.3390/curroncol31050182

Gibson, Amanda Jane Williams, Michelle Liane Dean, Ishjot Litt, Adrian Box, Winson Y. Cheung, and Vishal Navani. 2024. "Real-World Analysis of Post-Progression Treatment Patterns and Outcomes for EGFR Mutation-Positive Patients Treated with First-Line Osimertinib" Current Oncology 31, no. 5: 2427-2440. https://doi.org/10.3390/curroncol31050182

Gibson, A. J. W., Dean, M. L., Litt, I., Box, A., Cheung, W. Y., & Navani, V. (2024). Real-World Analysis of Post-Progression Treatment Patterns and Outcomes for EGFR Mutation-Positive Patients Treated with First-Line Osimertinib. Current Oncology, 31(5), 2427-2440. https://doi.org/10.3390/curroncol31050182